Travis Steed
Stock Analyst at B of A Securities
(2.75)
# 1,801
Out of 5,113 analysts
88
Total ratings
44.93%
Success rate
6.91%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNMD CONMED | Maintains: Neutral | $65 → $52 | $40.39 | +28.74% | 5 | Dec 8, 2025 | |
| MASI Masimo | Initiates: Neutral | $162 | $136.66 | +18.54% | 1 | Nov 17, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $194.70 | +34.05% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $315.35 | +1.47% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $125.12 | +19.88% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $80.68 | +5.35% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $84.80 | +6.13% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $21.35 | +49.88% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $19.07 | +135.97% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $3.61 | +1,146.54% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $353.11 | -10.79% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $292.88 | +0.72% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $31.70 | -49.53% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $21.80 | +51.38% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $90.40 | +76.99% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $561.89 | -43.94% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $2.52 | +217.46% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $11.71 | +113.49% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.56 | +483.79% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $65.91 | +89.65% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $98.48 | +47.24% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $96.11 | -46.94% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $13.05 | +313.79% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $64.84 | -66.07% | 1 | Jul 17, 2017 |
CONMED
Dec 8, 2025
Maintains: Neutral
Price Target: $65 → $52
Current: $40.39
Upside: +28.74%
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $136.66
Upside: +18.54%
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $194.70
Upside: +34.05%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $315.35
Upside: +1.47%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $125.12
Upside: +19.88%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $80.68
Upside: +5.35%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $84.80
Upside: +6.13%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $21.35
Upside: +49.88%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $19.07
Upside: +135.97%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $3.61
Upside: +1,146.54%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $353.11
Upside: -10.79%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $292.88
Upside: +0.72%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $31.70
Upside: -49.53%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $21.80
Upside: +51.38%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $90.40
Upside: +76.99%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $561.89
Upside: -43.94%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $2.52
Upside: +217.46%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $11.71
Upside: +113.49%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.56
Upside: +483.79%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $65.91
Upside: +89.65%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $98.48
Upside: +47.24%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $96.11
Upside: -46.94%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $13.05
Upside: +313.79%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $64.84
Upside: -66.07%